GILD - Gilead Sciences Inc

https://www.gilead.com

Buy Momentum: Bearish

Recent News

Bullish

Gilead Sciences ( GILD ) Exceeds Market Returns: Some Facts to Consider

Zacks Commentary • 3 days, 18 hours ago • score: 0.38

In the latest trading session, Gilead Sciences (GILD) closed at $117.86, marking a +2.26% move from the previous day.

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Uptrend

As of 2025-09-10 (Snapshot)

Gilead Sciences, Inc. is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV, hepatitis B, hepatitis C, and influenza, including Harvoni and Sovaldi.

52W High

$121.83

52W Low

$75.91

MA Status:

50D: Above 200D: Above

Beta (~1 neutral, <0.9 lower risk)

0.38

Valuation

Attractive

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

22.83

Forward P/E (<15 better)

13.28

EV/EBITDA (<8 favorable)

14.81

EV/Revenue (<3 favorable)

5.63

P/S (TTM) (<3 favorable)

4.95

P/B (<3 favorable)

7.26

Ownership

Institution‑heavy

Source: Overview

Insiders (1–5% typical)

0.10%

Institutions (25–75% balanced)

90.75%

Shares Outstanding

1,240,810,000

Float

1,238,176,000

Dividend Yield (2–6% sweet spot)

0.03%

Ex‑Dividend Date

2025-09-15

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

28,863,001,000

Gross Profit (TTM)

22,667,000,000

EPS (TTM)

5.04

Profit Margin (>10% good)

0.22%

Operating Margin (TTM) (higher better)

0.39%

ROE (TTM) (>15% strong)

0.33%

EPS YoY (Quarterly) (>10% good)

0.21

Revenue YoY (Quarterly) (>8% good)

0.02

Momentum

Bearish momentum

Value

0.3162

0.4323

Trend

Falling

Signal Cross

No cross

As of

Sep. 12, 2025